Types of Questions that we want? That we care about? That are meaningful?? Test different types of questions - can it analyze data from patient cases versus just questions? Can it interpret or report on literature results? Can it create educational questions (ie: multiple choice with wrong and a right answer)?

| **Patient Cases** | 1. BA is a 79 year old female with AML and a TP53 mutation. What is the best therapy for BA’s AML? 2. JA is a 23 year old male with core binding factor leukemia. The team is to start 3 + 7 induction. What dose of daunorubicin should be used? 3. JA is a 23 year old male with core binding factor leukemia. What is the preferred regimen for patients with favorable risk cytogenetics? How strong are the data to support this recommendation? 4. JA is a 23 year old male with core binding factor leukemia that finished 3 + 7 induction and is in a complete remission. What therapy should be given next? 5. JA is a 23 year old male with core binding factor leukemia that finished 3 + 7 induction and is in a complete remission. He has received 4 cycles of high dose cytarabine consolidation. The team would like to know if maintenance therapy is indicated and if so with what treatment? 6. BA started the 3 + 7 chemotherapy regimen for AML, when should a bone marrow biopsy be performed to assess for response? 7. JP is a 65 year old female with a past medical history of breast cancer who was treated with adriamycin and cyclophosphamide and paclitaxel. She is now diagnosed with AML. What is the most appropriate induction regimen for JP? 8. JP is a 65 year old female with a past medical history of breast cancer who was treated with adriamycin and cyclophosphamide and paclitaxel. She has completed induction chemotherapy and is in a complete remission. What therapy should she receive next? 9. OL is a 82 year old male who has been having progressive cytopenias. A bone marrow biopsy is performed that shows multilineage dysplasia and 12% blasts. Molecular studies reveal an NPM1 mutation. What treatment should OL receive to achieve a remission from their hematological disease? |
| --- | --- |
| **Questions Instead of Cases** | 1. What is the recommended treatment strategy for AML patients with an NPM1 mutation according to the most recent guidelines? 2. How do the latest guidelines suggest managing AML patients with adverse risk cytogenetics?" 3. According to current recommendations, how should relapsed or refractory AML be treated? 4. What do the most recent guidelines recommend for treating elderly patients with AML?" 5. How do current guidelines suggest integrating genetic information in the treatment planning for AML? 6. What are the specific criteria for considering a patient with AML for hematopoietic cell transplantation? 7. What are second-line treatment options if a patient with AML does not respond to initial chemotherapy? 8. What is the role of tyrosine kinase inhibitors in treating AML with FLT3 mutations? 9. How are targeted therapies used in the context of AML with IDH1/2 mutations? 10. According to current guidelines, how should minimal residual disease (MRD) in AML be monitored and managed? 11. What do the latest guidelines suggest for the maintenance therapy in AML patients who are not candidates of stem cell transplantation? 12. What do the latest guidelines suggest for the maintenance therapy in AML patients post stem cell transplantation? 13. According to recent guidelines, when should a second induction cycle be considered in AML treatment? 14. What regimens are recommended for AML for patients with relapsed or refractory disease? 15. How do the current guidelines suggest treating AML with myelodysplasia-related changes? 16. How do the current guidelines suggest treating secondary AML?" 17. How is the choice of treatment for AML influenced by a patient's age and general health? 18. What is the role of consolidation therapy post induction treatment in AML and what therapies are used? 19. Can you outline a typical treatment pathway for a newly diagnosed AML patient? 20. How should the response to AML treatment be monitored and how often? |
| **Literature / Clinical Trial Outcomes** | 1. What was the overall survival in the clinical trial of venetoclax in its phase III randomized controlled trial compared with the standard of care arm?" 2. Were there any significant differences in the safety profile of Venetoclax compared to standard care in its phase III trial?" 3. What was the response rate among AML patients in the phase III clinical trial of ivosidenib and azacitidine versus azacitidine? 4. How did the Phase II trial of Drug P impact event-free survival in AML patients? 5. What were the hematological toxicities reported in the clinical trial of liposomal cytarabine and daunorubicin (CPX-351) for AML patients? 6. How was quality of life assessed in the clinical trial of oral azacitidine for AML and what were the findings? 7. Could you elaborate on the rationale and evidence behind current first-line treatment recommendations for AML? 8. Which clinical studies support the use of daunorubicin at a dose of 90 mg/m2 for the treatment of AML? |
| **Education** | 1. Can you create a multiple-choice question about the treatment options for patients with FLT3+ AML 2. Could you generate a multiple-choice question about the results of the Phase III VIALE-A Trial for AML? 3. Can you generate a multiple-choice question about the treatment for AML patients with IDH1/2 mutations? 4. Could you create a multiple-choice question about the recommended first-line treatment for AML? 5. Can you formulate a multiple-choice question about how to manage the side effects of chemotherapy for AML patients? |

Documents we need to answer above questions??

1. NCCN guidelines
2. How I treat review
3. Maddy’s stewardship paper
4. ELNs AML guideline
5. WHO Myeloid classification
6. Phase III trials
7. UpToDate? Lol